Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.

Mohan M, Lin C, Guest E, Shilatifard A.

Nat Rev Cancer. 2010 Oct;10(10):721-8. doi: 10.1038/nrc2915. Epub 2010 Sep 16.

PMID:
20844554
2.

AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia.

Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, Washburn MP, Conaway JW, Conaway RC, Shilatifard A.

Mol Cell. 2010 Feb 12;37(3):429-37. doi: 10.1016/j.molcel.2010.01.026.

3.

The super elongation complex (SEC) family in transcriptional control.

Luo Z, Lin C, Shilatifard A.

Nat Rev Mol Cell Biol. 2012 Sep;13(9):543-7. doi: 10.1038/nrm3417. Epub 2012 Aug 16. Review.

PMID:
22895430
4.

Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia.

Dou Y, Hess JL.

Int J Hematol. 2008 Jan;87(1):10-8. doi: 10.1007/s12185-007-0009-8. Epub 2007 Dec 4.

PMID:
18224408
5.

A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.

DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, Cleary ML, Shilatifard A.

Blood. 2000 Dec 1;96(12):3887-93.

6.

A novel variant form of MLL-ELL fusion transcript with t(11;19)(q23;p13.1) in chronic myelomonocytic leukemia transforming to acute myeloid leukemia.

Kakihana K, Kubo F, Wakabayashi S, Kurosu T, Miki T, Murakami N, Miura O.

Cancer Genet Cytogenet. 2008 Jul 15;184(2):109-12. doi: 10.1016/j.cancergencyto.2008.04.001.

PMID:
18617060
7.

ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia.

Polak PE, Simone F, Kaberlein JJ, Luo RT, Thirman MJ.

Mol Biol Cell. 2003 Apr;14(4):1517-28. Erratum in: Mol Biol Cell.2003 May;14(5):following table of contents.

8.

The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.

Luo RT, Lavau C, Du C, Simone F, Polak PE, Kawamata S, Thirman MJ.

Mol Cell Biol. 2001 Aug;21(16):5678-87.

9.

Mixed lineage leukemia: roles in human malignancies and potential therapy.

Marschalek R.

FEBS J. 2010 Apr;277(8):1822-31. doi: 10.1111/j.1742-4658.2010.07608.x. Epub 2010 Mar 4. Review.

10.

MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

Monroe SC, Jo SY, Sanders DS, Basrur V, Elenitoba-Johnson KS, Slany RK, Hess JL.

Exp Hematol. 2011 Jan;39(1):77-86.e1-5. doi: 10.1016/j.exphem.2010.09.003. Epub 2010 Sep 18.

12.

The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis.

Daser A, Rabbitts TH.

Semin Cancer Biol. 2005 Jun;15(3):175-88. Review.

PMID:
15826832
13.

Misguided transcriptional elongation causes mixed lineage leukemia.

Mueller D, García-Cuéllar MP, Bach C, Buhl S, Maethner E, Slany RK.

PLoS Biol. 2009 Nov;7(11):e1000249. doi: 10.1371/journal.pbio.1000249. Epub 2009 Nov 24.

14.

The super elongation complex (SEC) and MLL in development and disease.

Smith E, Lin C, Shilatifard A.

Genes Dev. 2011 Apr 1;25(7):661-72. doi: 10.1101/gad.2015411. Review.

15.
16.

Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.

Shinobu N, Maeda T, Aso T, Ito T, Kondo T, Koike K, Hatakeyama M.

J Biol Chem. 1999 Jun 11;274(24):17003-10.

17.

Molecular pathogenesis of MLL-associated leukemias.

Eguchi M, Eguchi-Ishimae M, Greaves M.

Int J Hematol. 2005 Jul;82(1):9-20. Review.

PMID:
16105754
18.

An RNA polymerase II elongation factor encoded by the human ELL gene.

Shilatifard A, Lane WS, Jackson KW, Conaway RC, Conaway JW.

Science. 1996 Mar 29;271(5257):1873-6.

PMID:
8596958
19.

The molecular biology of mixed lineage leukemia.

Slany RK.

Haematologica. 2009 Jul;94(7):984-93. doi: 10.3324/haematol.2008.002436. Epub 2009 Jun 16. Review.

20.

The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions.

Pascual-Le Tallec L, Simone F, Viengchareun S, Meduri G, Thirman MJ, Lombès M.

Mol Endocrinol. 2005 May;19(5):1158-69. Epub 2005 Jan 13.

PMID:
15650021
Items per page

Supplemental Content

Write to the Help Desk